MCL

Advertisement
Rebecca AraujoOncology | December 17, 2021
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
Read More
DocWire News EditorsASH Annual Meeting and Exposition 2021 | May 2, 2023
At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | May 2, 2023
According to updated data from the phase I/II BRUIN study, presented at the 2021 American Society of Hematology Annual ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | May 2, 2023
Following its FDA approval in 2020 based on results from the ZUMA-2 trial, brexucabtagene autoleucel (brexu-cel) has ...
Rebecca AraujoOncology | December 10, 2021
Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 28, 2023
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
Rebecca AraujoASH Annual Meeting and Exposition 2021 | May 2, 2023
In the phase II CITADEL-205 study, roughly two-thirds of patients with relapsed/refractory and Bruton tyrosine kinase ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | May 2, 2023
A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) ...
Rebecca AraujoASH Annual Meeting and Exposition 2021 | May 2, 2023
Five-year follow-up data from the phase III MCL Younger trial found a sustained benefit associated with high-dose ...
Kaitlyn D’OnofrioOncology | July 5, 2023
Patients with mantle cell lymphoma who are unmarried, have a lower educational level, or with multiple comorbidities are ...
DocWire News EditorsASH Annual Meeting 2020 | April 3, 2023
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
DocWire News EditorsASH Annual Meeting 2020 | August 28, 2023
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
DocWire News EditorsASH Annual Meeting 2020 | April 6, 2023
Highly selective and irreversible Bruton’s tyrosine kinase inhibitor orelabrutinib was associated with continuous ...
DocWire News EditorsASH Annual Meeting 2020 | April 6, 2023
Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were ...
DocWire News EditorsASH Annual Meeting 2020 | April 6, 2023
Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, ...
DocWire News EditorsASH Annual Meeting 2020 | April 6, 2023
A combination treatment approach consisting of venetoclax, lenalidomide, and rituximab was well tolerated and ...
Kerri FitzgeraldOncology | November 19, 2019
The U.S. Food and Drug Administration (FDA) approved Brukinsa™ (zanubrutinib) capsules for the treatment of adults ...
Advertisement
Advertisement
Advertisement
Latest News

March 18, 2025